NPS Pharmaceuticals (NPSP)

14.28 +0.53  +3.85%  May 17, 8:00PM
Add to Watchlists Create an Alert

NPS Pharmaceuticals R&D Expense Quarterly:

24.04M for Dec. 31, 2012
View Full Chart

NPS Pharmaceuticals R&D Expense Quarterly Chart

    NPS Pharmaceuticals Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 24.04M
    Sept. 30, 2012 17.96M
    June 30, 2012 32.64M
    March 31, 2012 20.20M
    Dec. 31, 2011 21.56M
    Sept. 30, 2011 20.23M
    June 30, 2011 17.14M
    March 31, 2011 14.90M
    Dec. 31, 2010 16.14M
    Sept. 30, 2010 19.36M
    June 30, 2010 15.80M
    March 31, 2010 9.508M
    Dec. 31, 2009 13.25M
    Sept. 30, 2009 9.828M
    June 30, 2009 6.427M
    March 31, 2009 5.832M
    Dec. 31, 2008 4.837M
    Sept. 30, 2008 5.273M
    June 30, 2008 3.829M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
       
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro
    Sept. 30, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    NPSP R&D Expense Quarterly Benchmarks

    Companies
    Vertex Pharmaceuticals 218.10M
    Celgene Corporation 452.40M
    ACADIA Pharmaceuticals 4.901M

    NPSP R&D Expense Quarterly Rankings

    Overall 95th percentile
    343 of 7593
    Sector 87th percentile
    83 of 650 in Healthcare
    Industry 88th percentile
    28 of 237 in Biotechnology

    NPSP R&D Expense Quarterly Range, Past 5 Years

    Minimum 3.829M Jun 2008
    Maximum 32.64M Jun 2012
    Average 14.67M